In a landmark development for neuro-ophthalmology and bioelectronics, California-based Science Corporation has officially launched its Prima system in Europe. Following the receipt of the CE mark from the conformity assessment body DEKRA, the brain-computer interface (BCI) technology is now cleared for commercial use across 30 European nations. This milestone represents one of the most significant advancements in recent years for individuals suffering from geographic atrophy (GA) secondary to age-related macular degeneration (AMD)—a condition that has historically been characterized by the irreversible loss of central vision.
The Prima system is not merely a visual aid; it is a sophisticated, subretinal BCI designed to bypass damaged photoreceptors and interface directly with the brain’s visual pathways. For the millions globally whose lives have been constrained by the inability to read, recognize faces, or navigate independently, the commercial availability of Prima offers a long-awaited beacon of hope.
The Science Behind the Sight: How Prima Works
At the heart of the Prima system is a technological marvel that bridges the gap between mechanical engineering and biological neural networks. The system comprises two primary components: a micro-thin, subretinal photovoltaic implant and a pair of specialized augmented-reality glasses.
The implant, which is surgically positioned beneath the atrophic macula, is a wireless, light-sensitive array. The external glasses contain a camera and a micro-projector that capture the user’s visual field and translate it into near-infrared light. This light is projected onto the retinal implant, which then converts the photonic energy into electrical stimulation signals. These signals are sent directly to the intact neurons of the retina, which transmit the information to the brain, effectively "re-wiring" the visual cortex to interpret the input as sight.
Crucially, the glasses feature a proprietary magnification function specifically designed to assist with letter and object recognition. This integration of external processing and internal stimulation allows patients to regain a level of functional vision that was previously thought to be lost forever.
Chronology of Development: From Pixium to Commercialization
The journey of the Prima device is a story of strategic acquisition and rigorous clinical validation.
- The Foundations: The technology was originally developed by the French bioelectronics firm Pixium Vision, which spent years refining the subretinal photovoltaic array.
- The Strategic Acquisition: Recognizing the potential of this technology to transform lives, Science Corporation moved to consolidate its position in the BCI space. In April 2024, the company successfully acquired the intellectual property and related assets for the Prima implant from Pixium Vision, signaling a major push toward commercialization.
- Clinical Validation: Prior to the European launch, the system underwent a rigorous multi-center clinical study involving 38 participants across 17 sites in five countries. The data collected from these trials provided the backbone for the regulatory submission to DEKRA.
- Regulatory Milestone: With the achievement of the CE mark under the EU Medical Device Regulation (MDR), Science Corporation cleared the final hurdle for market entry in the European Economic Area.
- Global Expansion: While the European launch is currently underway—with the first surgical implantations scheduled to occur in Germany—the company is simultaneously engaging with the U.S. Food and Drug Administration (FDA). Having secured "Breakthrough Device" and "Humanitarian Use Device" designations, the company is actively working toward a U.S. market authorization path.
Supporting Data: Clinical Efficacy and Patient Outcomes
The clinical evidence supporting the Prima system is robust, demonstrating that the device provides more than just marginal improvements—it offers functional independence.
In the 12-month multi-center trial, participants showed a remarkable average improvement of 25.5 letters on the ETDRS (Early Treatment Diabetic Retinopathy Study) letter chart, which equates to over five lines of standard visual acuity test measurement.
Key metrics from the study included:
- Reading Recovery: 84% of patients regained the ability to read letters, numbers, and words, a task that was previously impossible due to their central vision loss.
- Significant Gains: 80% of patients experienced a logMAR gain of at least 0.2 (10 letters) after one year, with statistical significance reported at p<0.001, effectively confirming the device’s efficacy beyond chance.
- Safety Profile: One of the most critical findings for the surgical team was that the implantation procedure did not cause a decline in the patients’ existing mean natural vision. This safety threshold is paramount when treating elderly populations who often have complex ocular health profiles.
Implications for Global Public Health
Age-related macular degeneration remains a leading cause of blindness in the developed world. Geographic atrophy, the advanced, "dry" form of AMD, impacts more than five million people globally. As the global population ages, the prevalence of this condition is expected to rise sharply, placing a significant burden on healthcare systems and the quality of life of the elderly.
Addressing an Unmet Need
Until now, there have been few, if any, viable interventions for patients whose GA has progressed to the point of central blindness. Standard treatments focus on slowing progression, but rarely restore lost function. Prima shifts the paradigm from "management" to "restoration."
Economic and Social Impact
The ability to read, recognize faces, and navigate the world independently has profound social and economic implications. For the individual, it means the restoration of personal autonomy and a reduced reliance on caregivers. For the healthcare system, it represents a reduction in the long-term costs associated with blindness, such as specialized assisted living and intensive home care.
The BCI Revolution
Beyond AMD, the success of Prima serves as a "proof of concept" for the broader BCI industry. It demonstrates that surgically implanted, light-powered interfaces can be integrated into the human body to restore lost sensory input. This paves the way for further research into neural prosthetics for other sensory deficits and potentially complex motor control issues.
Looking Ahead: Market Access and Future Challenges
While the European launch is a historic victory, Science Corporation faces the complex task of navigating local reimbursement policies. In many European nations, medical device adoption is heavily dependent on the willingness of national health insurance programs to cover the costs of both the device and the specialized surgical training required for implantation.
Science Corporation has confirmed that country-specific reimbursement applications and clinical site activations are currently in progress. The selection of Germany as the location for the first commercial surgical implantation is strategic, given the country’s advanced neuro-ophthalmology infrastructure and established framework for innovative medical technology reimbursement.
In the United States, the road to the market remains the company’s next major objective. The FDA’s "Breakthrough Device" designation provides a prioritized review pathway, acknowledging that Prima addresses a life-altering condition with no existing alternative treatments. Industry analysts expect that the European clinical data will be instrumental in the ongoing discussions with U.S. regulators.
Conclusion: A New Horizon for Vision
The launch of the Prima system is a testament to the power of interdisciplinary innovation. By combining the precision of subretinal micro-electronics with the adaptability of the human brain, Science Corporation has successfully transitioned from the realm of speculative science to practical, life-changing medicine.
As the first patients in Europe prepare for their life-altering surgeries, the global medical community watches with great interest. If the results from the clinical trials are replicated in the real-world clinical setting, the Prima device could well become the standard of care for millions, transforming the experience of aging and blindness from one of inevitable loss to one of regained connection and independence. The era of the retinal BCI has officially begun.
About the Author
